Literature DB >> 29669844

Open issues on G3 neuroendocrine neoplasms: back to the future.

Maria Chiara Zatelli1, Elia Guadagno2, Erika Messina3, Fabio Lo Calzo4, Antongiulio Faggiano4, Annamaria Colao4.   

Abstract

The recent recognition that grade 3 (G3) neuroendocrine neoplasms (NENs) can be divided into two different categories according to the histopathological differentiation, that is G3 neuroendocrine tumors (NETs) and G3 neuroendocrine carcinomas (NECs) has generated a lot of interest concerning not only the diagnosis, but also the differential management of such new group of NENs. However, several issues need to be fully clarified in order to put G3 NETs and G3 NECs in the right place. The aim of this review is to focus on those issues that are still undetermined starting from the current knowledge, evaluating the available evidence and the possible clinical implications.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  G3; diagnosis; neuroendocrine tumors; prognosis

Mesh:

Year:  2018        PMID: 29669844     DOI: 10.1530/ERC-17-0507

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  3 in total

1.  Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Chiara Liverani; Alberto Bongiovanni; Laura Mercatali; Federica Pieri; Chiara Spadazzi; Giacomo Miserocchi; Giandomenico Di Menna; Flavia Foca; Sara Ravaioli; Alessandro De Vita; Claudia Cocchi; Giulio Rossi; Federica Recine; Toni Ibrahim
Journal:  Endocr Pathol       Date:  2021-01-06       Impact factor: 3.943

2.  Construction and validation of the prognostic model for patients with neuroendocrine cervical carcinoma: a competing risk nomogram analysis.

Authors:  Ai-Guo Jiang; Xu Cai
Journal:  BMC Cancer       Date:  2022-01-03       Impact factor: 4.430

3.  Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors.

Authors:  Zheng Zhang; Fei Wang; Zheng Li; Zeng Ye; Qifeng Zhuo; Wenyan Xu; Wensheng Liu; Mengqi Liu; Guixiong Fan; Yi Qin; Yue Zhang; Xuemin Chen; Xianjun Yu; Xiaowu Xu; Shunrong Ji
Journal:  BMC Surg       Date:  2022-05-10       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.